PMEL and neoplasm: We next investigated whether Δ7 MHC-I-expressing DCs could induce better antigen-specific anti-tumor responses in vivo using a well-established adoptive Pmel-1 T-cell transfer model to treat gp100-expressing B16 melanoma tumors [6], [26].